{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:17:54Z","timestamp":1762658274233,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Epidemiology and Population Health"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jeph.2025.202975","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T09:13:06Z","timestamp":1743498786000},"page":"202975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimation of the budget impact of the dual dispensing circuit of emicizumab in France: The HemiValue study"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-6767","authenticated-orcid":false,"given":"H.","family":"Leleu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Fraticelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ajjouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Touvron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Chamouard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jeph.2025.202975_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1056\/NEJM199401063300108","volume":"330","author":"Hoyer","year":"1994","journal-title":"New Engl J Med"},{"unstructured":"FranceCoag. Statistiques nationales. Donn\u00e9es d\u00e9mographiques : H\u00e9mophilie A. Accessed 31\/01\/2024, https:\/\/www.francecoag.org\/SiteWebPublic\/public\/stats\/stats_page.jsp?stat2=on&stat3=on","key":"10.1016\/j.jeph.2025.202975_bib0002"},{"issue":"S6","key":"10.1016\/j.jeph.2025.202975_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"null","key":"10.1016\/j.jeph.2025.202975_bib0004","first-page":"941","article-title":"Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom","volume":"13","author":"Carroll","year":"2019","journal-title":"Pat Prefer Adhere"},{"issue":"1","key":"10.1016\/j.jeph.2025.202975_bib0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10198-021-01339-4","article-title":"Costs and management of patients with hemophilia A in France: the Hemraude study","volume":"23","author":"Laurendeau","year":"2022","journal-title":"Eur J Health Eco"},{"issue":"9","key":"10.1016\/j.jeph.2025.202975_bib0036","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"New Engl J Med"},{"issue":"9","key":"10.1016\/j.jeph.2025.202975_bib0037","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"s1","key":"10.1016\/j.jeph.2025.202975_bib0006","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2516.2009.02175.x","article-title":"Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies","volume":"16","author":"Coppola","year":"2010","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.jeph.2025.202975_bib0007","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D'Angiolella","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"16","key":"10.1016\/j.jeph.2025.202975_bib0008","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"unstructured":"COMMISSION DE LA TRANSPARENCE. Emicizumab. Avis. 11 juillet 2018.","key":"10.1016\/j.jeph.2025.202975_bib0009"},{"unstructured":"COMMISSION DE LA TRANSPARENCE. Emicizumab. Avis. 2 octobre 2019.","key":"10.1016\/j.jeph.2025.202975_bib0010"},{"doi-asserted-by":"crossref","unstructured":"Young G, Liesner R, Chang T, et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127\u20132138. doi:10.1182\/blood.2019001869","key":"10.1016\/j.jeph.2025.202975_bib0011","DOI":"10.1182\/blood.2019001869"},{"issue":"1","key":"10.1016\/j.jeph.2025.202975_bib0012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/hae.14129","article-title":"Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France","volume":"27","author":"Polack","year":"2021","journal-title":"Haemophilia"},{"unstructured":"COMMISSION DE LA TRANSPARENCE. Emicizumab. Extension d'indication. Avis sur les m\u00e9dicaments. 10 mai 2023.","key":"10.1016\/j.jeph.2025.202975_bib0013"},{"key":"10.1016\/j.jeph.2025.202975_bib0014","article-title":"sant\u00e9 publique. Cinqui\u00e8me partie. Livre Ier. Titre II. Chapitre VI","author":"Code de la","year":"2022","journal-title":"Article L5126-4"},{"key":"10.1016\/j.jeph.2025.202975_bib0015","doi-asserted-by":"crossref","first-page":"e43091","DOI":"10.2196\/43091","article-title":"Evaluation of the care pathway in the context of the dispensing of Emicizumab (Hemlibra) in community pharmacies in France: protocol for a cross-sectional study based on the Kirkpatrick model","volume":"12","author":"Fraticelli","year":"2023","journal-title":"JMIR Res Protoc"},{"unstructured":"MHEMO. Accompagnement de l'instauration d'un double circuit de dispensation d'emicizumab, en pharmacie de ville et \u00e0 l'h\u00f4pital. Accessed 15\/02\/2024,https:\/\/mhemo.fr\/actualites\/accompagnement-de-linstauration-dun-double-circuit-de-dispensation-demicizumab-en-pharmacie-de-ville-et-a-lhopital\/","key":"10.1016\/j.jeph.2025.202975_bib0016"},{"issue":"6","key":"10.1016\/j.jeph.2025.202975_bib0017","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1111\/hae.14857","article-title":"Evaluation of the care pathway in the context of the dispensing of emicizumab (Hemlibra) in community and hospital pharmacies in France: A patient satisfaction survey","volume":"29","author":"Chamouard","year":"2023","journal-title":"Haemophilia"},{"issue":"4","key":"10.1016\/j.jeph.2025.202975_bib0018","doi-asserted-by":"crossref","first-page":"e172","DOI":"10.1016\/j.phacli.2022.10.684","article-title":"Emicizumab, premier traitement de l'h\u00e9mophilie disponible en officine","volume":"57","author":"Fontaine","year":"2022","journal-title":"Le Pharmacien Clinicien"},{"unstructured":"Observatoire national interminist\u00e9riel de la s\u00e9curit\u00e9 routi\u00e8re. Observatoire des vitesses. Accessed 01\/02\/2024, https:\/\/www.onisr.securite-routiere.gouv.fr\/etudes-et-recherches\/comportements-en-circulation\/observations\/observatoire-des-vitesses","key":"10.1016\/j.jeph.2025.202975_bib0019"},{"unstructured":"ADATEC. Le co\u00fbt r\u00e9el de la voiture. Accessed 26\/12\/2024, http:\/\/www.adetec-deplacements.com\/cout-reel-voiture-ADETEC.pdf","key":"10.1016\/j.jeph.2025.202975_bib0020"},{"unstructured":"INSEE. Emploi et revenus des ind\u00e9pendants. Edition 2020 Accessed 01\/02\/2024, https:\/\/www.insee.fr\/fr\/statistiques\/4470764?sommaire=4470890","key":"10.1016\/j.jeph.2025.202975_bib0021"},{"unstructured":"INSEE. Informations rapides N\u00b0 295. Accessed 01\/02\/2024, https:\/\/www.insee.fr\/fr\/statistiques\/5871518","key":"10.1016\/j.jeph.2025.202975_bib0022"},{"unstructured":"Assurance Maladie. M\u00e9dicaments rembours\u00e9s dans le cadre de la r\u00e9trocession hospitali\u00e8re - retroced'AM - 2010 \u00e0 2022. Accessed 01\/02\/2024, https:\/\/assurance-maladie.ameli.fr\/etudes-et-donnees\/medicaments-retrocession-hospitaliere-retrocedam","key":"10.1016\/j.jeph.2025.202975_bib0023"},{"year":"2018","author":"R\u00e9publique","series-title":"Arr\u00eat\u00e9 du 12 novembre 2018 modifiant l\u2019arr\u00eat\u00e9 du 4 ao\u00fbt 1987 relatif aux prix et aux marges des m\u00e9dicaments remboursables et des vaccins et des allerg\u00e8nes pr\u00e9par\u00e9s sp\u00e9cialement pour un individu","key":"10.1016\/j.jeph.2025.202975_bib0024"},{"unstructured":"territoires. Mdlt\u00e9edlcd. Donn\u00e9es et \u00e9tudes statistiques. Pour le changement climatique, l'\u00e9nergie, l'environnement, le logement, et les transports. Accessed 23\/05\/2024, https:\/\/www.statistiques.developpement-durable.gouv.fr\/donnees-sur-les-immatriculations-des-vehicules","key":"10.1016\/j.jeph.2025.202975_bib0025"},{"unstructured":"Transilien. Le calcul des \u00e9missions de CO2. Accessed 23\/05\/2024, https:\/\/www.transilien.com\/fr\/page-corporate\/calcul-emissions-co2","key":"10.1016\/j.jeph.2025.202975_bib0026"},{"key":"10.1016\/j.jeph.2025.202975_bib0027","article-title":"Quel lien entre pouvoir d\u2019achat et consommation des m\u00e9nages enconsommation des m\u00e9nages en France aujourd\u2019hui\u202f? Note de conjoncture","author":"Billot","year":"2019","journal-title":"INSEE"},{"unstructured":"R\u00e9publique Fran\u00e7aise. Code de la sant\u00e9 publique. Chapitre 1 : conditions de l'exercice de la pharmacie d'officine (Articles L568 \u00e0 L595). 2000. Accessed 25\/03\/2025. https:\/\/www.legifrance.gouv.fr\/codes\/section_lc\/LEGITEXT000006072665\/LEGISCTA000006155247\/1992-12-11\/","key":"10.1016\/j.jeph.2025.202975_bib0028"},{"issue":"2","key":"10.1016\/j.jeph.2025.202975_bib0029","first-page":"151","article-title":"Double dispensation des antir\u00e9troviraux en ville: bilan \u00e0 un an dans l'agglom\u00e9ration lilloise 1","year":"2001","journal-title":"Sant\u00e9 publique"},{"issue":"1","key":"10.1016\/j.jeph.2025.202975_bib0030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10198-016-0785-2","article-title":"Social\/economic costs and quality of life in patients with haemophilia in Europe","volume":"17","author":"Cavazza","year":"2016","journal-title":"Eur J Health Eco"},{"unstructured":"INSEE. La France et ses territoires. \u00c9dition 2021. Accessed 06\/02\/2024, https:\/\/www.insee.fr\/fr\/statistiques\/5020062?sommaire=5040030","key":"10.1016\/j.jeph.2025.202975_bib0031"},{"issue":"1","key":"10.1016\/j.jeph.2025.202975_bib0032","first-page":"79","article-title":"Les produits de sant\u00e9. La r\u00e9trocession hospitali\u00e8re ou la d\u00e9licate ma\u00eetrise du co\u00fbt des m\u00e9dicaments vendus par les \u00e9tablissements de sant\u00e9","author":"PEIGNE","year":"2005","journal-title":"Revue de droit sanitaire et social"},{"issue":"5","key":"10.1016\/j.jeph.2025.202975_bib0033","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pharma.2018.05.001","article-title":"La r\u00e9trocession, une activit\u00e9 rentable mais \u00e0 risques","volume":"76","author":"Laoubi","year":"2018","journal-title":"Annal Pharmaceutiques Fran\u00e7aises"},{"issue":"2","key":"10.1016\/j.jeph.2025.202975_bib0034","doi-asserted-by":"crossref","DOI":"10.1007\/s10269-005-0167-3","article-title":"Les diff\u00e9rentes cat\u00e9gories de m\u00e9dicaments et la r\u00e9trocession hospitali\u00e8re:(r) \u00e9volutions r\u00e9glementaires","volume":"7","author":"Paubel","year":"2005","journal-title":"Oncologie"},{"issue":"1","key":"10.1016\/j.jeph.2025.202975_bib0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.pharma.2023.08.001","article-title":"Le double circuit de dispensation, exemple des traitements antir\u00e9troviraux : quelle pertinence ?","volume":"82","author":"Tribaudeau","year":"2024","journal-title":"Annales Pharmaceutiques Fran\u00e7aises"}],"container-title":["Journal of Epidemiology and Population Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950433325001703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950433325001703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:12:57Z","timestamp":1762657977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950433325001703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2950433325001703"],"URL":"https:\/\/doi.org\/10.1016\/j.jeph.2025.202975","relation":{},"ISSN":["2950-4333"],"issn-type":[{"type":"print","value":"2950-4333"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimation of the budget impact of the dual dispensing circuit of emicizumab in France: The HemiValue study","name":"articletitle","label":"Article Title"},{"value":"Journal of Epidemiology and Population Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jeph.2025.202975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"202975"}}